AstraZeneca
AZN
1,141 hedge funds and large institutions have $33.8B invested in AstraZeneca in 2024 Q1 according to their latest regulatory filings, with 120 funds opening new positions, 482 increasing their positions, 340 reducing their positions, and 94 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 482 | Existing positions reduced: 340
28% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 94
2% more call options, than puts
Call options by funds: $480M | Put options by funds: $470M
1% more funds holding
Funds holding: 1,130 → 1,141 (+11)
0.23% less ownership
Funds ownership: 16.28% → 16.06% (-0.23%)
1% less capital invested
Capital invested by funds: $34B → $33.8B (-$235M)
8% less funds holding in top 10
Funds holding in top 10: 13 → 12 (-1)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$596M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$491M |
| 3 |
Neuberger Berman Group
New York
|
+$168M |
| 4 |
Millennium Management
New York
|
+$151M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$147M |
Top Sellers
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$903M |
| 2 |
Morgan Stanley
New York
|
-$659M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$157M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$129M |
| 5 |
D.E. Shaw & Co
New York
|
-$103M |
AZN Hedge Fund Activity: Q1 2024 in Review
1,141 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2024, worth a combined $33.8B — down 0.69% from $34B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new AZN positions and 94 closed out — a net gain of 26 holders — while 482 added to existing stakes and 340 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $596M. The largest seller was GQG Partners, cutting an estimated $903M.
- 1,141 institutional investors held AstraZeneca (AZN) as of Q1 2024, up from 1,130 in Q4 2023.
- Funds reported $33.8B of AstraZeneca stock for Q1 2024, down 0.69% quarter-over-quarter.
- 120 funds opened new AstraZeneca positions in Q1 2024 and 94 closed out, a net change of +26 holders.
- The largest AstraZeneca buyer in Q1 2024 was T. Rowe Price Associates, an estimated $596M added.
- The largest AstraZeneca seller in Q1 2024 was GQG Partners, an estimated $903M sold.
Based on aggregated 13F filings for Q1 2024.